Related Experiment Video
Updated: Aug 18, 2026

Measuring the Carotid to Femoral Pulse Wave Velocity (Cf-PWV) to Evaluate Arterial Stiffness
Published on: May 3, 2018
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in
Kara A Nerenberg1, Kelly B Zarnke2, Alexander A Leung3
1Division of General Internal Medicine, Departments of Medicine, Obstetrics and Gynecology, Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Insights
The 2018 Hypertension Canada guidelines offer updated evidence-based recommendations for managing high blood pressure in adults and children. Key updates include new guidelines for pregnancy, revised stroke treatment targets, and new recommendations for heart failure management.
Area of Science:
- Cardiology
- Internal Medicine
- Public Health
Background:
- Hypertension Canada annually publishes evidence-based guidelines for hypertension management.
- The 2018 guidelines consolidate adult and pediatric recommendations and introduce new pregnancy-specific guidelines.
- Previous guidelines focused on general hypertension management, with specific updates for acute ischemic stroke.
Purpose of the Study:
- To present the 2018 Hypertension Canada guidelines for the diagnosis, assessment, prevention, and treatment of hypertension.
- To incorporate new evidence and recommendations into clinical practice for hypertension management.
- To provide updated guidance on blood pressure monitoring, cardiovascular risk assessment, and pharmacotherapy for heart failure.
Main Methods:
- Annual review and synthesis of evidence by Hypertension Canada committees.
- Inclusion of 5 new guidelines and revision of 1 existing guideline.
- Incorporation of recommendations for validated wrist devices, standardized blood pressure measurement, and specific pharmacologic agents.
Main Results:
- Combined adult and pediatric guidelines published in one document.
- New guidelines for pregnancy-specific hypertension.
- Revised guideline on blood pressure targets for thrombolysis in acute ischemic stroke.
- Inclusion of wrist devices for blood pressure measurement in individuals with large arm circumference.
- Guidance on follow-up blood pressure measurements using standardized methods and electronic devices.
- Emphasis on global cardiovascular risk assessment for all individuals with hypertension.
- Recommendation for angiotensin receptor-neprilysin inhibitor use in specific heart failure patients.
Conclusions:
- The 2018 guidelines provide comprehensive, updated recommendations for hypertension management.
- New guidelines address specific populations and conditions, including pregnancy and heart failure.
- Emphasis on standardized measurement, risk assessment, and advanced pharmacotherapy aims to improve patient outcomes.
Abstract:
Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis, assessment, prevention, and treatment of hypertension in adults and children. This year, the adult and pediatric guidelines are combined in one document. The new 2018 pregnancy-specific hypertension guidelines are published separately. For 2018, 5 new guidelines are introduced, and 1 existing guideline on the blood pressure thresholds and targets in the setting of thrombolysis for acute ischemic stroke is revised. The use of validated wrist devices for the estimation of blood pressure in individuals with large arm circumference is now included. Guidance is provided for the follow-up measurements of blood pressure, with the use of standardized methods and electronic (oscillometric) upper arm devices in individuals with hypertension, and either ambulatory blood pressure monitoring or home blood pressure monitoring in individuals with white coat effect. We specify that all individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure. Finally, an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in individuals with heart failure (with ejection fraction < 40%) who are symptomatic despite appropriate doses of guideline-directed heart failure therapies. The specific evidence and rationale underlying each of these guidelines are discussed.
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management

